Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloprost infusion for septic shock-induced endotheliopathy
2019-001131-31Phase 2Completed
- Sponsor
- Capital Region Blood Center
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in septic shock and endotheliopathy comparing Ilomedin with Placebo (2 arms). Primary endpoint: Mean daily modified Sequential Organ Failure Assessment score. Started Mar 2019; status: completed.
02
Drugs
iloprost
03
Conditions
septic shockendotheliopathy
Beyond the preview
Go deeper on 2019-001131-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001131-31.